Corpus overview


MeSH Disease

Pneumonia (97)

COVID-19 (96)

Fever (29)

Death (19)

Lymphopenia (18)

HGNC Genes

SARS-CoV-2 proteins

ProteinN (2)


SARS-CoV-2 Proteins
    displaying 41 - 50 records in total 97
    records per page

    Short-Term Corticosteroids in SARS-CoV2 Patients: Hospitalists' Perspective

    Authors: Vijairam Selvaraj; Kwame Dapaah-Afriyie; Arkadiy Finn; Timothy Flanigan

    doi:10.1101/2020.06.19.20109173 Date: 2020-06-23 Source: medRxiv

    Background: Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties. There is a hyperinflammatory response involved in the clinical course of patients with pneumonia MESHD due to SARS-CoV2. To date, there has been no definite therapy for COVID-19 MESHD. We reviewed the charts of SARS-CoV2 patients with pneumonia MESHD and moderate to severely elevated CRP HGNC and worsening hypoxemia MESHD who were treated with early, short-term dexamethasone. Methods: We describe a series of 21 patients who tested positive for SARS-CoV2 and were admitted to The Miriam Hospital in Providence and were treated with a short course of dexamethasone, either alone or in addition to current investigative therapies. Results: CRP HGNC levels decreased significantly following the start of dexamethasone from mean initial levels of 129.52 to 40.73 mg/L at time of discharge. 71% percent of the patients were discharged home with a mean length of stay of 7.8 days. None of the patients had escalation of care, leading to mechanical ventilation. Two patients were transferred to inpatient hospice facilities on account of persistent hypoxemia MESHD, in line with their documented goals of care. Conclusions: A short course of systemic corticosteroids among inpatients with SARS-CoV2 with hypoxic respiratory failure MESHD was well tolerated, and most patients had improved outcomes. This limited case series may not offer concrete evidence towards the benefit of corticosteroids in COVID-19 MESHD. However, patients positive response to short-term corticosteroids demonstrates that they may help blunt the severity of inflammation MESHD and prevent a severe hyperinflammatory phase, in turn reducing the length of stay, ICU admissions, and healthcare costs.

    Prolonged low-dose methylprednisolone in patients with severe COVID-19 MESHD pneumonia

    Authors: Francesco Salton; Paola Confalonieri; Pierachille Santus; Sergio Harari; Raffaele Scala; Simone Lanini; Valentina Vertui; Tiberio Oggionni; Antonella Caminati; Vincenzo Patruno; Mario Tamburrini; Alessandro Scartabellati; Mara Parati; Massimiliano Villani; Dejan Radovanovic; Sara Tomassetti; Claudia Ravaglia; Venerino Poletti; Andrea Vianello; Anna Talia Gaccione; Luca Guidelli; Rita Raccanelli; Donato Lacedonia; Paolo Lucernoni; Maria Pia Foschino Barbaro; Stefano Centanni; Michele Mondoni; Matteo Davi; Alberto Fantin; Xueyuan Cao; Lucio Torelli; Antonella Zucchetto; Marcella Montico; Annalisa Casarin; Micaela Romagnoli; Stefano Gasparini; Martina Bonifazi; Pierlanfranco D'Agaro; Alessandro Marcello; Danilo Licastro; Barbara Ruaro; Maria Concetta Volpe; Reba Umberger; Gianfranco Umberto Meduri; Marco Confalonieri

    doi:10.1101/2020.06.17.20134031 Date: 2020-06-20 Source: medRxiv

    Background In hospitalized patients with COVID-19 MESHD pneumonia MESHD, progression to acute respiratory failure MESHD requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation MESHD is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for ICU and mortality. Methods We conducted a multicenter, observational study to explore the association between exposure to prolonged, low-dose, MP treatment and need for ICU referral, intubation or death MESHD within 28 days (composite primary endpoint) in patients with severe COVID-19 MESHD pneumonia MESHD admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein HGNC ( CRP HGNC) levels. Results Findings are reported as MP (n=83) vs. control (n=90). The composite primary endpoint was met by 19 vs. 40 [adjusted hazard ratio (HR) 0.41; 95% confidence interval (CI): 0.24-0.72]. Transfer to ICU and need for invasive MV was necessary in 15 vs. 27 (p=0.07) and 14 vs. 26 (p=0.10), respectively. By day 28, the MP group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 plus-or-minus sign 9.0 vs. 17.5 plus-or-minus sign 12.8; p=0.001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP HGNC levels. The complication rate was similar for the two groups (p=0.84). Conclusion In patients with severe COVID-19 MESHD pneumonia MESHD, early administration of prolonged MP treatment was associated with a significantly lower hazard of death MESHD (71%) and decreased ventilator dependence. Randomized controlled studies are needed to confirm these findings.

    Clinical Characteristics and Prognosis of Patients with COVID-19 MESHD Combineded with or without Diabetes, Hypertension or Coronary

    Authors: Haoxiang Li; Jianguo Zhang; Jinhui Zhang; Ling Yang; Dong Wang; Li Zhao; Xia Deng; Guoyue Yuan

    doi:10.21203/ Date: 2020-06-19 Source: ResearchSquare

    Bcakground: This study was to investigate the clinical characteristics and prognosis of COVID-19 MESHD patients combined with or without major chronic diseases MESHD like diabetes MESHD, hypertension MESHD or coronary. Methods: We retrospectively analyzed 183 patients with COVID-19 MESHD diagnosed at First People's Hospital of Jiangxia District (FPHJD) in Wuhan, China attended by Affiliated Hospital of Jiangsu University supporting medical team from February 1, 2020 to March 15, 2020. Patients were divided into simple COVID-19 MESHD group(n=134), COVID-19 MESHD combined with diabetes MESHD, hypertension MESHD or coronary group(n=49). Besides, COVID-19 MESHD patients with diabetes MESHD, hypertension MESHD or coronary were further classified into severe pneumonia MESHD group(n=23) and common pneumonia MESHD group(n=26), death MESHD group(n=17) and survival group(n=32). The prognosis of COVID-19 MESHD patients was evaluated by analyzing the clinical data and the results of laboratory tests. Results: 183 patients were included in this study, of whom 166 were discharged and 16 died in hospital. 49 (26.92%) patients had a comorbidity, with hypertension MESHD being the most common [37 (20.33%) patients], followed by diabetes MESHD [25 (13.74%) patients] and coronary heart disease MESHD [4 (2.2%) patients]. Compared with simple COVID-19 MESHD group, the proportion of history of chronic respiratory system disease MESHD, age, D-dimer, procalcitonin, C-reactive protein HGNC, myoglobin HGNC, cardiac troponin I, creatine kinase MB, lactate dehydrogenase, white blood cell count, neutrophil count, neutrophil percentage, blood urea nitrogen, creatinine and mortality rate were significantly higher in COVID-19 MESHD combined with chronic diseases group, whereas lymphocyte count, lymphocyte percentage and alanine transferase were significantly lower in COVID-19 MESHD combined with chronic diseases group. Among COVID-19 MESHD patients with chronic diseases MESHD, D-dimer, procalcitonin, C-reactive protein, myoglobin, cardiac troponin I, lactate dehydrogenase, white blood cell count, neutrophil count, neutrophil percentage, blood urea nitrogen, death MESHD rate was significantly higher in severe pneumonia MESHD group than common pneumonia group. While lymphocyte count and lymphocyte percentage were significantly lower in severe pneumonia MESHD group than common pneumonia group. Besides, we found that the proportion of history of chronic respiratory system disease MESHD, D-dimer, procalcitonin, myoglobin HGNC, cardiac troponin I, creatine kinase MB, lactate dehydrogenase, neutrophil count, neutrophil percentage, blood urea nitrogen were significantly higher in death group compared with survival group, whereas lymphocyte count and lymphocyte percentage were significantly lower in survival group. In COVID-19 MESHD combined with chronic diseases group, univariate logistic regression showed that the risk for severe pneumonia MESHD were D-dimer, C-reactive protein HGNC, lactate dehydrogenase, white blood cell count, neutrophil count and neutrophil percentage. Univariate logistic regression also showed that the risk for death MESHD were D-dimer, lactate dehydrogenase, white blood cell count, neutrophil count, neutrophil percentage and blood urea nitrogen. Multivariate regression logistic showed that lactate dehydrogenase were independent risk factors for death among COVID-19 MESHD patients combined with chronic diseases MESHD. Cox regression analysis showed that compared with simple COVID-19 MESHD group, the RR(95% CI) in COVID-19 MESHD patients combined with diabetes MESHD, hypertension MESHD, and coronary were 2.187 (1.141~4.191) for death MESHD (P<0.05). Conclusion: Among COVID-19 MESHD patients combined with diabetes MESHD, hypertension MESHD or coronary, the risk factors for severe pneumonia MESHD were D-dimer, C-reactive protein HGNC, lactate dehydrogenase, white blood cell count, neutrophil count and neutrophil percentage, whereas the risk factors for death MESHD were D-dimer, lactate dehydrogenase, white blood cell count, neutrophil count, neutrophil percentage and blood urea nitrogen. Moreover, lactate dehydrogenase were independent risk factors for death MESHD. The mortality rate of COVID-19 MESHD patients combined with diabetes MESHD, hypertension MESHD or coronary was higher than that of simple COVID-19 MESHD patients.

    Apply Four Laboratory Characteristics to Classify Critical Patients With COVID-19 MESHD After Admission

    Authors: anping guo; Zejian Kuang; Ying Wang; Dongxue Luo; Xiaoying Zheng; Benjun Yang; Tian Yang; Jianwei Dai; Canhong Wen; Haizhu Tan

    doi:10.21203/ Date: 2020-06-19 Source: ResearchSquare

    Background The sudden outbreaking of COVID-19 MESHD worldwide has brought into sharp increased burden of economic and treatment in worldwide. All confirmed patients with different severity not only share the limited healthcare systems simultaneously but increase the risk of cross-infection MESHD among patients and health care workers. Hence, effective separation of critical COVID-19 MESHD patients from the common COVID-19 MESHD will be the key to success for ensuring critical patients to obtain treatment priorities and avoiding cross-infections MESHD in the hospital.Methods: A total of 105 patients with complete medical records were collected, including 84 blood samples of patients who confirmed in the First Affiliated Hospital of the University of Science and Technology at Anhui and 25 blood samples of patients in two hospitals at Shantou. Series of machine learning tools were introduced to explore and validate the most significant laboratory characteristics. Meanwhile, we compared it to three current popular assessment systems for pneumonia MESHD by using three methods, including the AUC index, NRI index and the net benefit.Results: We identified four significant potential laboratory characteristics for the classification of critical patients, including C-reactive protein HGNC, albumin, globulin, and sodium levels. The results also suggested the accurate and prediction efficacy of these selected indicators are the highest.Conclusions In conclusion, four easily available and low-cost laboratory characteristics appear to be import predictors of classification in critical patients after hospital admission. They guide therapeutic options and help clinicians make clinical decisions. Hence, we believe that such classification is essential for a more rational allocation scarce medical resource.

    GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 MESHD pneumonia

    Authors: Luis Corral; Alberto Bahamonde; Francisco Arnaiz delas Revillas; Julia Gomez-Barquero; Jesica Abadia-Otero; Carmen Garcia-Ibarbia; Victor Mora; Ana cerezo-hernandez; Jose L Hernandez; Graciela Lopez-Muniz; Fernando Hernandez-Blanco; Jose M Cifrian; Jose M Olmos; Miguel Carrascosa; maria Carmen farinas; Jose A Riancho; - Glucocovid investigators

    doi:10.1101/2020.06.17.20133579 Date: 2020-06-18 Source: medRxiv

    Background. We aimed to determine whether a 6-day course of intravenous methylprednisolone (MP) improves outcome in patients with SARS CoV-2 infection MESHD at risk of developing Acute Respiratory Distress Syndrome MESHD ( ARDS MESHD). Methods. Multicentric, partially randomized, preference, open-label trial, including adults with COVID-19 MESHD pneumonia MESHD, impaired gas exchange and biochemical evidence of hyper-inflammation MESHD. Patients were assigned to standard of care (SOC), or SOC plus intravenous MP [40mg/12h 3 days, then 20mg/12h 3 days]. The primary endpoint was a composite of death MESHD, admission to the intensive care unit (ICU) or requirement of non-invasive ventilation (NIV). Results. We analyzed 85 patients (34, randomized to MP; 22, assigned to MP by clinician preference; 29, control group). Patient age (mean 68{+/-}yr) was related to outcome. The use of MP was associated with a reduced risk of the composite endpoint in the intention-to-treat, age-stratified analysis (combined risk ratio -RR- 0.55 [95% CI 0.33-0.91]; p=0.024). In the per-protocol analysis, RR was 0.11 (0.01-0.83) in patients aged 72 yr or less, 0.61 (0.32-1.17) in those over 72 yr, and 0.37 (0.19-0.74, p=0.0037) in the whole group after age-adjustment by stratification. The decrease in C-reactive protein HGNC levels was more pronounced in the MP group (p=0.0003). Hyperglycemia MESHD was more frequent in the MP group. Conclusions A short course of MP had a beneficial effect on the clinical outcome of severe COVID-19 MESHD pneumonia MESHD, decreasing the risk of the composite end point of admission to ICU, NIV or death MESHD.

    Temporal clinical and laboratory response to interleukin-6 HGNC receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 MESHD pneumonia

    Authors: Daria S Formina; Mar'yana A Lysenko; Irina P Beloglazova; zinaida Y Mutinova; Nataliya G Poteshkina; Inna V Samsonova; Tat'yana S Kruglova; Anton A Chernov; Alexander V Karaulov; Michael M Lederman

    doi:10.1101/2020.06.12.20122374 Date: 2020-06-12 Source: medRxiv

    Abstract: Background:. Emerging evidence links morbidity and mortality of pandemic COVID-19 MESHD pneumonia MESHD to an inflammatory cytokine storm. Methods: Eighty nine patients with COVID-19 MESHD pneumonia MESHD and heightened systemic inflammation MESHD (elevated serum C reactive protein HGNC and interleukin-6 HGNC levels) were treated with Tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor HGNC. Results: Clinical and laboratory improvement was seen comparing baseline and 1-2 day post-infusion indices. Among 72 patients not receiving mechanical ventilation, NEWS2 scores fell from 5 to 2 (p <0.001) C reactive protein HGNC levels fell from 95 to 14 mg/L (p <0.001) and lymphocyte counts rose from 900 to 1000/uL (p=0.036). Sixty three of 72 patients were discharged from hospital, one patient died, and 8 remained in hospital at time of writing. Among 17 patients receiving mechanical ventilation, despite a rapid decrease in CRP HGNC levels from 89 to 35 mg/L (p = 0.014) and early improvements in NEWS2 scores in 10 of 17, ten patients died and seven remain in hospital at time of writing. Overall, mortality was only seen in patients who had markedly elevated CRP HGNC levels (>30 mg/L) and low lymphocyte counts (<1000/uL) before TCZ administration. Conclusions: Inflammation MESHD and lymphocytopenia MESHD are linked to mortality in COVID-19 MESHD. Inhibition of IL-6 HGNC activity by administration of Tocilizumab, an anti IL-6 receptor antibody is associated with rapid improvement in both CRP HGNC and lymphocyte counts and in clinical indices. Controlled clinical trials are needed to confirm the utility of IL-6 HGNC blockade in this setting. Additional interventions will be needed for patients requiring mechanical ventilation.

    Accuracy of routine biomarkers and blood leucocytes count to assist diagnosis of COVID-19 MESHD-associated pneumonia in adult patients visiting the emergency department

    Authors: Cécile Maincent; Frédéric Berthier; Ryan Lukas Farhad; Cristel Fissore-Magdelein; Claire Claire Dittlot; Nathalie Beau; Jérémy Lépine; Marjorie Lorillou; Matthieu Dietz; Mathieu Liberatore; Atul Pathak; Marc Marc Faraggi; Sylvie Chaillou-Orpitz; Olivia Keita-Perse; Gilles Chironi; Christophe Perrin; Yann-Erick Claessens

    doi:10.21203/ Date: 2020-06-12 Source: ResearchSquare

    Background To investigate whether routine biomarkers and blood leucocytes count could assist diagnosis of COVID-19 MESHD-associated pneumonia MESHD in adult patients visiting the emergency department (ED). Methods This monocentre retrospective study enrolled 254 patients with nasopharyngeal RT-PCR for SARS-COV-2, routine biomarkers (D-dimers, fibrinogen HGNC, C-reactive protein HGNC, procalcitonin, NTpro-BNP, cTnT HGNC-hs) and blood cell counts. Sensitivity and specificity were evaluated. An adjudication committee classified diagnostic probability as certain, probable, unlikely, and excluded, based on all available data, then distributed in 2 categories: high (certain and probable) and low probability (unlikely and excluded). Results Between 25 th of February and 15 th of April, 2020, 254 of 388 patients could be analyzed. The adjudication committee classified 46 patients as definite, 18 as probable, 64 as unlikely, and 126 as excluded, corresponding to 64 high and 190 low probability. High and low probability patients differed for fibrinogen HGNC (P<0.0005) and white blood cell counts, notably leucocytes (P=0.0015), neutrophilic (P=0.0036), lymphocytes (P=0.0057), eosinophilic (P=0.027), and basophilic (P<0.001) counts. In a multivariate analysis, basophilic count < 25/µL (OR 3.048 [95%CI; 1.34-6.919]), neutrophilic count < 4000 /µL (OR 5.525 [95%CI; 2.20-13.855], and fibrinogen HGNC > 3g/L (OR 6355 [95%CI; 2.01-20.079] were independently associated with the diagnosis. Negative predictive values were 0.98 and 0.93 combining fibrinogen HGNC ( < 3g/L) and eosinophilic count ( < 80/µL), and fibrinogen HGNC and basophilic count ( < 25/µL), respectively. Conclusion Changes in fibrinogen HGNC and white blood cells, notably basophilic count, showed interesting performance for the diagnosis COVID-19 MESHD associated pneumonia. Combining fibrinogen HGNC with either eosinophilic or basophilic count was helpful to exclude the diagnosis.

    Comparison of Clinical, Para-clinical and Laboratory Findings in Survived and Deceased Patients with COVID-19 MESHD: Diagnostic Role of Inflammatory Indications in Determining the Severity of Illness

    Authors: Mohsen Rokni; Kazem Ahmadikia; Somaye Asghari; Shahabodin Mashaei; Fahimeh Hassanali

    doi:10.21203/ Date: 2020-06-12 Source: ResearchSquare

    Background: Since December 2019, when a cluster of pneumonia MESHD cases due to SARS-CoV-2 initially emerged in Wuhan city and then rapidly spread throughout the world, the necessity for data concerning the clinical and paraclinical features of Iranian patients with COVID-19 MESHD was highlighted. Therefore, we aimed to compare the clinical, paraclinical and laboratory evidences of deceased patients with survival group. Methods: We extracted data regarding 233 patients with laboratory-confirmed COVID-19 MESHD from Buali Hospital in Iran; clinical/paraclinical and inflammatory indexes data were collected and analyzed. The data of laboratory examinations and chest CT findings were compared between deceased and survived patients. Results: The mean age of the patients was 49.8 years and 64% of our patients were male. The acute respiratory distress syndrome MESHD occurred in 64 patients, 52 who were admitted to the ICU, which all of them underwent invasive mechanical ventilation, and 28 who died. Lymphopenia MESHD (79%), neutrophilia (79%), and thrombocytopenia MESHD (21%) were the most frequently observed laboratory findings of the deceased group on admission. Most patients (68%) had a high systematic immune-inflammation MESHD (SII) index of >500 and increased C-reactive protein HGNC level (88%). Levels of inflammatory indexes such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and SII were documented to be significantly elevated in the deceased group when compared with the patients who survived (P< 0.0001, P< 0.001, P< 0.0001, respectively). The most commonly presented symptoms were fever MESHD (70%) and cough MESHD (63%) on admission. Headache MESHD was uncommon (11%). Ground-glass opacity with consolidation (mixed) was the most common radiologic finding on chest CT (51%). No radiographic or CT abnormality was found in 15 of 204 patients (7%). Conclusion: Small fraction of patients with COVID-19 MESHD may present without fever MESHD and abnormal radiologic findings. Elevated NLR, PLR and SII can be considered as prognostic and risk stratifying factor of severe form of disease.

    Diagnostic classification of coronavirus disease 2019 MESHD ( COVID-19 MESHD) and other pneumonias using radiomics features in CT chest images

    Authors: Ning Yang; Faming Liu; Chunlong Li; Wenqing Xiao; Shuangcong Xie; Shuyi Yuan; Wei Zuo; Xiaofen Ma; Guihua Jiang

    doi:10.21203/ Date: 2020-06-11 Source: ResearchSquare

    We propose a classification method using the radiomics features of CT chest images to identify patients with coronavirus disease 2019 MESHD ( COVID-19 MESHD) and other pneumonias MESHD. The chest CT images of two groups of participants (90 COVID-19 MESHD patients and 90 other pneumonias MESHD patients) were collected, and the two groups of data were manually drawn to outline the region of interest (ROI) of pneumonias MESHD. The radiomics method was used to extract textural features and histogram features of the ROI and obtain a radiomics features vector from each sample. Finally, using the radiomics features as an input, a support vector machine (SVM) model was constructed to classify patients with COVID-19 MESHD and patients with other pneumonias MESHD. This model used 20 rounds of 10-fold cross-validation for training and testing. In the COVID-19 MESHD patients, correlation analysis (multiple comparison correction—Bonferroni correction, p<0.05/7) was also conducted to determine whether the textural and histogram features were correlated with the laboratory test index of blood, i.e., blood oxygen, white blood cell, lymphocytes, neutrophils, C-reactive protein HGNC, hypersensitive C-reactive protein HGNC, and erythrocyte sedimentation rate. The results showed that the proposed method had a classification accuracy as high as 88.33%, sensitivity of 83.56%, specificity of 93.11%, and an area under the curve of 0.947. This proved that the radiomics features were highly distinguishable, and this SVM model can effectively identify and diagnose patients with COVID-19 MESHD and other pneumonias MESHD. The correlation analysis results showed that some texture features were positively correlated with WBC, NE, and CRP HGNC and also negatively related to SPO2H and NE.

    Laboratory findings in coronavirus disease 2019 MESHD ( COVID-19 MESHD) patients: a comprehensive systematic review and meta-analysis

    Authors: Mohammad Karimian; Amirreza Jamshidbeigi; Gholamreza Badfar; Milad Azami

    doi:10.1101/2020.06.07.20124602 Date: 2020-06-08 Source: medRxiv

    Background: In early December 2019, the first patient with COVID-19 MESHD pneumonia MESHD was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19 MESHD. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 MESHD patients. Material and methods: The present meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. This protocol is registered with the code CRD42019145410 in PROSPERO International Database. Results: Finally, 52 studies involving 5490 patients with COVID-19 MESHD entered the meta-analysis process. The prevalence of leukopenia MESHD, lymphopenia MESHD, elevated c-reactive protein HGNC ( CRP HGNC), elevated erythrocyte sedimentation rate (ESR), elevated serum amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence of elevated interleukin-6 HGNC was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 HGNC was 62.0% (95%CI: 51.1-71.6), reduced CD8 HGNC was 42.7% (95%CI: 32.2-53.9). The prevalence of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide ( BNP HGNC) was 48.9% (95%CI: 30.4-67.7), elevated blood urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia MESHD was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6). Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19 MESHD. The results show that lymphopenia MESHD, elevated CRP HGNC, elevated ESR, elevated ferritin, elevated serum amyloid A, elevated BNP HGNC, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4 HGNC, reduced CD8 HGNC, elevated D-dimer, reduced PT, elevated interleukin-2 HGNC, elevated interleukin-6 HGNC, elevated LDH and hyperglycemia MESHD are the common findings at the time of admission.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.